

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

**COMP/M.6091 - GALENICA / FRESENIUS MEDICAL CARE / VIFOR FRESENIUS
MEDICAL CARE RENAL PHARMA JV
SECTION 1.2**

Description of the concentration

The Commission has received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) 139/2004 by which Galenica Ltd. (“Galenica”) and Fresenius Medical Care AG & Co. KGaA (“Fresenius”) would acquire joint control over a newly created full-function joint venture (“JV”).

The primary business activities of the undertakings concerned are:

- for Galenica: development, manufacturing and marketing of pharmaceutical products worldwide, operation of pharmacies, logistical and database services.
- for Fresenius: provision of dialysis products, such as haemodialysis machines, dialyzers and related disposable products, as well as the provision of dialysis services.
- For JV: research, development, marketing and distribution of pharmaceutical products against hyperphosphatemia and iron deficiency anaemia for patients suffering primarily from CKD Stages 3, 4 and 5.